AI Science Tracker
EN

Automated full-process pipeline via multiparametric MRI for tumor segmentation, molecular subtype classification and prognostic factor analysis in breast cancer.

Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China · 30 Apr 2026 · medicine

Discovery

Automated full-process pipeline via multiparametric MRI for tumor segmentation, molecular subtype classification and prognostic factor analysis in breast cancer.

Source check: Source checked. Not independent scientific confirmation.

Finding: A multiparametric MRI pipeline combined 3D U-Net tumor segmentation with 2D ResNet biomarker classification in 484 breast-cancer patients across three institutions; the study reports validation including external performance measures. This is retrospective image-analysis validation, not prospective clinical benefit.

Technology: A 3D U-Net segments tumors from multiparametric MRI, and a 2D ResNet classifies molecular biomarkers from the resulting image features.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
A 3D U-Net segments tumors from multiparametric MRI, and a 2D ResNet classifies molecular biomarkers from the resulting image features.
Test and result
Europe PMC abstract reports 484 patients at three institutions and validation with AUC/Dice measures; the exact metric values are omitted here.
Limitation / still unknown
Prospective clinical utility and treatment benefit were not evaluated; the reported external validation remains retrospective
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13247932/ · https://pubmed.ncbi.nlm.nih.gov/42273105/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.